Cogentix Medical (CGNT) Upgraded to “Hold” at Zacks Investment Research

Cogentix Medical (NASDAQ:CGNT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday.

According to Zacks, “Cogentix Medical, Inc. is a medical device company which designs, develops, manufactures and markets proprietary technologies serving the urology market. The company’s primary product consists of Urgent(R) PC Neuromodulation System and EndoSheath System. It operates primarily in Orangeburg, New York, The Netherlands and the United Kingdom. Cogentix Medical, Inc., formerly known as Vision-Sciences Inc., is headquartered in Orangeburg, New York. “

CGNT has been the topic of a number of other research reports. TheStreet raised shares of Cogentix Medical from a “d+” rating to a “c” rating in a research note on Thursday, November 9th. Aegis began coverage on shares of Cogentix Medical in a research note on Friday, December 1st. They issued a “buy” rating and a $4.75 target price on the stock. Finally, Roth Capital began coverage on shares of Cogentix Medical in a research note on Wednesday, November 8th. They issued a “buy” rating and a $4.00 target price on the stock. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $4.06.

Cogentix Medical (CGNT) traded up $0.05 during midday trading on Monday, reaching $2.80. 30,717 shares of the company were exchanged, compared to its average volume of 44,897. The company has a market capitalization of $167.49, a PE ratio of -6.83 and a beta of 0.88. Cogentix Medical has a twelve month low of $1.55 and a twelve month high of $3.34.

A hedge fund recently raised its stake in Cogentix Medical stock. Northern Trust Corp lifted its stake in shares of Cogentix Medical, Inc. (NASDAQ:CGNT) by 0.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 73,926 shares of the medical device company’s stock after purchasing an additional 326 shares during the period. Northern Trust Corp owned approximately 0.12% of Cogentix Medical worth $129,000 at the end of the most recent reporting period. 13.29% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Cogentix Medical (CGNT) Upgraded to “Hold” at Zacks Investment Research” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/12/cogentix-medical-cgnt-upgraded-to-hold-at-zacks-investment-research.html.

About Cogentix Medical

Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).

Get a free copy of the Zacks research report on Cogentix Medical (CGNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cogentix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply